Wilson Sonsini Goodrich & Rosati advised Vida Ventures on IP matters related to the transaction. Third Arc Bio Inc., a biotech company, announced a $165 million...
You must be a Standard 1 Year member to access this content.
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Foresite Capital on the transaction. CG Oncology, Inc. announced the close of an oversubscribed $105 million crossover financing round, co-led...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Venrock Healthcare Capital Partners on IP matters related to the transaction. Upstream Bio, a clinical-stage biotech company, announced the completion of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal while Morrison & Foerster LLP represented RA Capital and OrbiMed as lead investors. Janux Therapeutics...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal. Janux Therapeutics, a developer of safe, effective novel immunotherapies using its proprietary Tumor Activated T...
You must be a Standard 1 Year member to access this content.
